1
2
3
IMMUNOCORE HOLDINGS PLC-ADR (NASDAQ)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
交易时间表 (UTC)
开放
立即关闭
关闭日期
开幕日期
于
-
这将显示您所在时区的开放时间
(UTC)
滴答声 | IMCR |
合同价值 | 100 shares |
最大杠杆率 | 1:5 |
掉期历史
日期 | Short Swap (%) | Long Swap (%) | 无数据 |
---|
最低交易量 | 0.01 地段 |
最大交易量 | 100 地段 |
套期保值保证金 | 50% |